Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), ChemBioMed Interdisciplinary Research Center at Nanjing University, School of Chemistry and ...

A survey of the nation's oncologists showed that professional burnout has reached a new high (59% vs 45% in 2013), and fewer ...

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer.

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of ...

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

A spokesperson for the Cholangiocarcinoma Foundation writes that experimental cancer trials saved her life and could save the ...

San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and ...